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Introduction
The analysis of circulating cell- free DNA (cfDNA) is the 
most promising noninvasive alternative to conventional 
serial tissue biopsy for the analysis of the molecular features 
of tumors [1]. Several lines of evidence support the poten-
tial clinical utility of this method of liquid biopsy in colo-
rectal cancer (CRC), particularly at advanced stages [2]. 
Several studies demonstrated that elevated cfDNA levels 
in plasma, together with a heterogeneous pattern of hotspot 
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Abstract
Next- generation sequencing (NGS) has been proposed as a suitable tool for 
liquid biopsy in colorectal cancer (CRC), although most studies to date have 
focused almost exclusively on sequencing of panels of potential clinically action-
able genes. We evaluated the clinical value of whole- exome sequencing (WES) 
of cell- free DNA (cfDNA) circulating in plasma, with the goal of identifying 
differential clinical profiles in patients with CRC. To this end, we applied an 
original concept, “differential presence of exons” (DPE). We determined differ-
ences in levels of 379 exons in plasma cfDNA and used DPE analysis to cluster 
and classify patients with disseminated and localized disease. The resultant bio-
informatics analysis pipeline allowed us to design a predictive DPE algorithm 
in a small subset of patients that could not be initially classified based on the 
selection criteria. This DPE suggests that these nucleic acids could be actively 
released by both tumor and nontumor cells as a means of intercellular com-
munication and might thus play a role in the process of malignant transforma-
tion. DPE is a new technique for the study of plasma cfDNA by WES that 
might have predictive and prognostic value in patients with CRC.
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mutation status (including the KRAS, NRAS, BRAF, and 
EGFR genes, among others), provide a strong predictor 
of clinical prognostic value [3–6]. Thus, by surveillance 
of cfDNA in plasma, it is possible to anticipate disease 
progression months ahead of standard imaging follow- up 
[7, 8]. Similarly, cfDNA was used in a recent study to 
reflect tumor molecular dynamics in the drug response 
of metastatic patients with CRC, tracking the evolution 
of resistance mutations in KRAS pathway genes at different 
time points over the course of anti- EGFR therapy [2].
Circulating tumor DNA (ctDNA) fragments represent 
a minor proportion of the total cfDNA and, therefore, 
require extremely sensitive and specific detection tech-
niques. In this regard, next- generation sequencing (NGS) 
has attracted increasing interest over the last few years. 
Most studies focused on NGS for liquid biopsy described 
targeted- sequencing approaches, aimed at analyzing panels 
of genes with potential value for clinical management of 
different kinds of cancers, including CRC [9, 10]. NGS 
of cfDNA in plasma has recently been applied in patients 
with CRC, with the goal of identifying serial changes in 
mutational profiles and tumor load fluctuations, facilitat-
ing early detection of recurrence [11, 12]. Studies using 
these approaches revealed that different cancers originate 
detectable ctDNA alterations, the majority of which are 
clinically actionable by currently approved drugs. In addi-
tion, these approaches are useful for monitoring of treat-
ment and disease progression. It must be noted, however, 
that tumors sometimes shed an insufficient amount of 
DNA for analysis, especially, but not exclusively, at early 
stages of disease [11, 13]. Clinical sensitivity seems to be 
significantly affected by the surgical excision of primary 
tumors, mutational heterogeneity, and tumor burden, 
rendering analysis of mutations inefficient in cancer patients 
with low levels of ctDNA [14].
These observations led us to look at NGS from a dif-
ferent perspective. Searching for known mutations by 
targeted deep sequencing is the most common strategy 
but could be unnecessarily costly and has limited potential 
for tumors that shed low levels of DNA. Accordingly, we 
pursued an alternative approach: exome sequencing per-
formed at a relatively shallower depth, with the goal of 
obtaining a more general overview of circulating DNA 
in plasma, including both known and unknown charac-
teristics of cancer. The aim of this study was to compare 
other differential features, in terms of cfDNA rather than 
SNPs, in CRC patients with disseminated or localized 
disease, using whole- exome sequencing. This approach 
represents a new strategy that broadens the scope of NGS 
applications in liquid biopsy, reducing costs and making 
it more feasible for translation to clinical scenarios. Our 
approach focused on identifying differential traits or genetic 
profiles in cfDNA, termed “differential presence of exons” 
(DPE), related to metastasis, that could be useful for 
predicting disease progress in patients with CRC.
Materials and Methods
Patients
Thirty patients with CRC were selected, following the 
criteria shown in Table 1, from January to December 
2014 in the Department of General Surgery at Fundación 
Jiménez Díaz University Hospital, Madrid, Spain, accord-
ing to a protocol approved by the Ethics Committee for 
Clinical Research of this Institution. Informed consent 
was obtained from each subject, and all investigations 
were performed in accordance with the principles embod-
ied in the World Medical Association Declaration of 
Helsinki.
Subjects were classified into three groups: metastatic 
patients (M; n = 10), nonmetastatic patients (N; n = 10), 
and a group containing unclassifiable patients according 
to the selection criteria in Table 1 (U; n = 10). Briefly, 
we considered as unclassifiable those patients with T4 
locally advanced disease and/or affected nodes, but no 
Table 1. Criteria for patient selection.
Non- metastatic cohort (N) Metastatic cohort (M) Unclassifiable cohort (U)
Inclusion criteria Age >18 years 
Candidates for elective surgery 
Provided informed consent 
Histological diagnosis: colon adenocarcinoma of enteroid pattern
• pT1-pT3 
• pN0
• M0 (established by PET-CT)
• R0 
• Any T or N
• M1: liver metastasis with an 
enteroid adenocarcinoma 
pattern, established 
histologically
• pT4 and/or pN1-pN2
• M0 (established by PET-CT)
Exclusion criteria Previous cancers in other locations 
Lynch syndrome or other hereditary intestinal cancers
R0: whole tumor was removed. PET- CT, Positron Emission Tomography–Computed Tomography.
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signs of distant metastasis affecting other organs or peri-
toneal carcinomatosis determined by PET- CT (M0), except 
p04, who simultaneously had colorectal and bladder cancer 
with hepatic involvement, whose primary origin could 
not be determined, and p23 (T3N0M0), who had a cancer 
debut with intestinal obstruction requiring colonostomy. 
Due to the diagnostic doubts generated by these patients, 
they were classified in group U.
Sample collection and processing
Blood samples were collected before surgery in EDTA 
tubes and centrifuged at 1800 × g for 10 min. Plasma 
obtained from the first centrifugation was centrifuged again 
at 3000 × g for 10 min, aliquoted, and stored at −80°C 
prior to analysis.
Library preparation, exome capture, and 
sequencing
Circulating cfDNA was extracted from plasma using the 
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). 
Concentration, quantity, and integrity of cfDNA were 
estimated prior to use. The size distribution of cfDNA 
fragments was determined using a 2100 BioAnalyzer 
(Agilent Technologies, Santa Clara, CA). Additional shear-
ing was not performed because the majority of circulating 
DNA fragments in plasma are naturally short. Library 
preparation and specific exome capture were performed 
using the SeqCap EZ HGSC VCRome Kit (Roche 
NimbleGen, Basel, Switzerland).
Libraries were hybrid- captured using biotinylated probes. 
Adapter DNA sequences were placed on both ends, yield-
ing a total length of 126 nucleotides, and exomes were 
sequenced on the Illumina NextSeq500 platform (Illumina, 
Inc, San Diego, CA) with 75 bp paired- end reads. Library 
preps and sequencing were performed at the Genomic 
Facility of the Scientific Park of Madrid, Spain.
Data analysis
Around 974 M of 2 × 75 nt reads were obtained, with 
an average read depth of 40–80× per sample. Quality 
analyses were performed using the FastQC software [15]. 
Reads were aligned against the H. sapiens genome (hg38) 
using Bowtie [16] with the following parameters: - v 3 - k 
1 –best.
Detection of differentially present exons
cfDNA sequencing data were processed as in a typical 
RNA- seq pipeline, but the strategy was aimed at detecting 
DPE rather than gene expression. This analysis was 
performed using the R package “EdgeR” [17]. Counts 
were calculated using the HTSeq- count software [18].
Statistical methods were based on generalized linear 
models (glm), which are suitable for multifactor experi-
ments of any complexity. The glm functions can test for 
differential expression using either likelihood ratio tests 
(LRT) [17] or quasi- likelihood F- tests (QLF) [19]. The 
DPE for a P- value of P ≤ 0.005 was selected. MA plots 
are shown for selected DPE.
DPE clustering and principal components 
analysis (PCA)
To verify that all samples were behaving properly, nor-
malized presence values were obtained for every exon for 
each sample using EdgeR (Counts Per Million, CPM). 
Once normalized presence values were calculated, they 
were used to cluster the samples using Ward’s method 
[20]. Principal components analysis (PCA) was performed 
using an R script developed in- house, using normalized 
DPE presence levels.
Random forest (RF) classification
Random forest (RF) classification was implemented with 
an R script using the “randomForest” package [21]. Briefly, 
two samples from M and N were randomly selected and 
extracted from each group, respectively, using the eight 
remaining samples (16 samples in total) as a “training 
set” to generate a predictive algorithm. One hundred clas-
sifications were performed by iteration of this process, 
and the mean value of the obtained probabilities was 
calculated. The accuracy of the resulting model was tested 
by checking its ability to correctly classify previously 
extracted samples into their corresponding groups of 
origin.
Pathway analysis
First, we used PANTHER (Protein ANalysis THrough 
Evolutionary Relationships, http://pantherdb.org) [22], 
a web- based software for relating gene sequence to 
specific molecular functions, biological processes, and 
pathways. We submitted to PANTHER the list of dif-
ferentially present genes for each group and performed 
a functional classification in specific biological pathways. 
A Wilcoxon–Mann–Whitney test was performed for 
paired samples using the percentage of genes classified 
in the same pathway against the total number of genes 
in each group.
On the other hand, data were analyzed with Ingenuity 
Pathway Analysis (IPA®; Qiagen, http://www.qiagenbioin-
formatics.com) [23], a software application for the analysis 
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and interpretation of data derived from omics experiments. 
The list of over- represented genes for each group was 
imported into IPA and mapped to the IPA knowledge 
database. We performed the core analysis for predicting 
pathways and molecular functions affected, based on gene 
expression. The significance of the association between 
the dataset and the specific pathways was determined by 
right- tailed Fisher’s exact test (P < 0.05). A Wilcoxon–
Mann–Whitney test was performed for paired samples to 
analyze whether the percentage of genes from both groups 
were differentially distributed in the main function 
categories.
Statistical analysis
Nonparametric Kolmogorov–Smirnov and Wilcoxon–
Mann–Whitney tests for significance were performed in 
R to test differences in DNA concentration in plasma 
(cutoff P- value of P < 0.05). LRT and QLF tests were 
performed for DPE with a P- value of P ≤ 0.005. A 
Wilcoxon–Mann–Whitney test for paired samples for 
PANTHER analysis of pathways was performed and right- 
tailed Fisher’s exact test for IPA with a cutoff P- value of 
P < 0.05 for both tests. A Wilcoxon–Mann–Whitney test 
for paired samples was also performed for gene distribu-
tion in IPA main function categories.
Data availability
Whole- exome sequencing data that support the findings 
of this study have been deposited in the European 
Genome- phenome Archive (EGA) with the accession num-
ber EGAS00001002687.
Results
cfDNA isolation from plasma and NGS
Circulating cfDNA was successfully extracted from all 
plasma samples, obtaining a variable concentration of DNA 
ranging from 13.76 to 1602.90 pg/μL. Median DNA con-
centration in metastatic patients was higher than in non-
metastatic patients (Fig. 1A), although this difference was 
not statistically significant. Median DNA concentration in 
unclassifiable patients was slightly elevated with respect 
to the other groups. BioAnalyzer plots revealed a cfDNA 
size distribution with a pattern that suggested nucleosomal 
fragmentation. We obtained cfDNA with median fragment 
lengths of 173 and 342 bp, once sequencing adapter lengths 
(126 nt) were  subtracted. One additional peak of 511 bp 
was observed in only two patients in our cohort (Fig. 1B).
The total number of reads per patient ranged from 45 
to 87 million with a read length of 76 bp (Table S1; see 
supporting information for further details). Quality analyses 
of reads using the FastQC software (Phred+33 quality score) 
revealed that median and mean base quality were >28, 
although the quality of some bases was as low as 22. As 
usual, some inaccuracy was present in the first 10–11 bases.
GC content varied between 46 and 50, and the per-
centage of aligned reads ranged from 64% to 78%. Thus, 
we considered it unnecessary to trim or filter the reads 
Figure 1. (A) Box plot of DNA concentration in plasma of patients with colorectal cancer. Median concentration of cell- free DNA (cfDNA) in plasma 
was higher in metastatic patients than in nonmetastatic patients. The distribution of cfDNA concentration in unclassifiable patients shared 
characteristics with both classified groups. (B) Size distribution of a cfDNA library from a patient, showing a nucleosomal laddering pattern with 
fragment sizes of 302, 472, and 641 bp (adapter sequences included).
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to improve quality. A schematic representation of the 
experimental workflow is shown in Figure 2.
DPE analysis
We identified a set of exons whose differential presence 
in plasma allowed us to distinguish between groups M 
and N. This set of exons was later used to classify every 
member of the U group within group M or N.
Differential presence of exons was analyzed with EdgeR, 
using either QLF or LRT, with a threshold of P ≤ 0.005 
for M–N comparison. A total of 366 and 297 exons were 
obtained, respectively, yielding 379 exons overall, including 
unique and common exons. MA plots for selected DPE 
are represented in Figure 3.
A total number of 379 differentially present exons were 
found, 162 over- represented in group N and 217 over- 
represented in group M. Then, we examined in which 
genes were located these exons. Considering that some 
exons belong to the same gene, finally, we identified a 
total of 333 genes, of which 147 were over- represented 
in group N and 186 in group M (Table S2; see sup-
porting information for the complete list of genes).
DPE clustering
Clustering of normalized DPE was performed by Ward’s 
method; the resultant tree is included in Figure 4. Patients 
were mostly grouped properly, maintaining the separation 
between the M and N samples.
Next, we performed PCA. Figure 5 shows a bidimen-
sional plot with the two- first principal components. The 
figure shows that groups M and N are clearly separated 
and clustered properly. U group patients are located 
between the limits of both groups, supporting the idea 
that patients belonging to the U group share characteristics 
with both metastatic and nonmetastatic patients.
These results encouraged us to develop a predictive 
algorithm to classify samples from patients. To achieve 
this goal, a RF classification was obtained after 100 itera-
tions, extracting two randomly selected samples from each 
group (M and N), and generating a predictive model, 
with the 16 remaining samples (eight per group) as a 
training set. A verification test was performed to confirm 
that the algorithm was able to classify extracted samples 
into their corresponding groups of origin, by calculating 
the average probabilities of belonging to one group or 
another (Table S3; see supporting information for check-
ing test results). The extracted samples were correctly 
identified, and the highest mean probability was 0.68.
Subsequently, we tried to classify the patients in group 
U using this algorithm, but the probabilities obtained 
were near 0.5 in all cases (Table S4). p04 had liver metas-
tasis from unknown origin, and p58 was the only patient 
who developed metastasis during the follow- up period. 
Two other patients (p63 and p66) were at very high risk 
Figure 2. Schematic workflow of the experimental procedure. Cell- free DNA (cfDNA) was isolated from plasma of patients with colorectal cancer 
(CRC). Exome capture was performed before sequencing, and the resultant reads were subsequently aligned to the reference genome sequence 
(hg38). A pipeline for NGS data analysis was applied to cfDNA from patients with CRC.
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of local recurrence and peritoneal metastasis according 
to the eligibility criteria; accordingly, they underwent pro-
phylactic treatment (second- look plus hyperthermic intra-
peritoneal chemotherapy, HIPEC). These four patients 
were then correctly classified by our DPE algorithm as 
belonging to the M group.
Pathway analysis
We performed two different pathway analyses to gain 
further insight into the functional annotation of the 333 
over- represented genes. Using PANTHER, we found that 
most genes were not included in any specific pathway 
and only 139 were classified in 56 specific pathways. In 
addition, the distribution of genes from M and N groups 
in these pathways followed similar patterns (P = 0.3916). 
From the 56 identified pathways, only 17 had more than 
one percent of genes involved (Fig. S1).
IPA showed that over- represented genes in both groups 
were related to three major biological functions: “organ-
ismal injury and abnormalities,” “cancer,” and “gastroin-
testinal disease.” In addition, a higher percentage of genes 
Figure 3. MA plots for selected differentially present exons (DPE; P ≤ 0.005). The log ratio of fold- change (FC) is plotted on the y- axis, and the average 
of the normalized counts (counts per million) is plotted on the x- axis. A total of 379 exons were obtained with EdgeR, combining two different 
methods: (A) likelihood ratio tests (LRT) (297 exons) and (B) quasi- likelihood f- tests (QLF) (366 exons). Over- represented exons in the metastatic (M) 
and nonmetastatic (N) groups are indicated by ▲ and ■, respectively.
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from group N took part in other functions different from 
the three major common categories mentioned above 
(P = 0.02537) (Tables S5 and S6; Fig. S2). Regarding 
networks, over- represented genes in group N were associ-
ated to 11 networks whereas those in group M were 
related to other 14 different networks (Tables S7 and S8).
Discussion
Historically, one of the main challenges in the analysis 
of circulating cfDNA is achievement of sufficient sensitivity 
and reproducibility despite the low concentrations of this 
type of DNA in plasma. The development of improved 
NGS methodologies probably will help to definitively 
overcome this limitation. In this study, we used one such 
methodology to analyze the plasma of CRC patients; the 
quality of reads and percentage of correctly aligned 
sequences supported the feasibility of our approach.
The size distribution reflected typical nucleosomal lad-
dering. The predominant peak had a length around 173 bp, 
probably corresponding to mononucleosomal DNA, 
whereas other cfDNA molecules were present in multiples 
of this size, characteristic of a di- and trinucleosomal 
fragmentation pattern, as previously described [24]. Three 
possible sources of cfDNA have been proposed: apoptosis, 
necrosis, and active release [25]. However, most authors 
focused on cell death as the primary origin [26, 27]. In 
this study, the oligonucleosomal laddering pattern in the 
size distribution and the trace quantities of sequences larger 
than 10,000 bp suggested that cfDNA largely originated 
from apoptosis, and only minimally from necrosis. These 
results are in agreement with previous observations [13].
Our main objective was to evaluate whole- exome 
sequencing as a tool for identifying differential traits or 
profiles between CRC patients with disseminated (M) or 
localized disease (N). Interestingly, the differential features 
detected by our model could come from both tumor- and 
nontumor- derived DNA. This point emphasizes the origi-
nality of our proposal and its main difference from prior 
studies, which focused almost exclusively on cancer- related 
genetic alterations. To date, NGS has been applied to 
liquid biopsy for CRC by targeted deep sequencing of 
panels of potential clinically actionable genes carrying 
mutations known to be relevant to cancer development 
and progression, such as single- nucleotide variants and 
indels, which could also be used as markers for monitor-
ing of tumor burden [11, 12, 28, 29]. Whole- genome 
sequencing has also been used to search for chromosomal 
alterations, including copy number changes and amplifica-
tions of cancer driver genes in cfDNA of patients with 
CRC [13, 30, 31]. For example, MET amplification was 
Figure 4. Clustering of patients by Ward’s Method, using normalized 
values of differentially present exons (DPEs). Metastatic (M) and 
nonmetastatic (N) patients were clearly separated into two groups, 
whereas unclassifiable patients (U) were located in between, indicating 
that they shared traits with both groups. Patients who were recurrence- 
free after the 2- year follow- up period are marked with an asterisk (*); 
remarkably, these patients tend to group together. (!) high- risk patients 
treated by hyperthermic intraperitoneal chemotherapy (HIPEC); (#) 
correctly predicted metastasis; (+) exitus.
Figure 5. Bidimensional principal components analysis (PCA) plot. 
Metastatic (M) and nonmetastatic (N) patients are properly clustered 
and clearly separated. Unclassifiable patients (U) form another group 
between the limits of M and N, likely due to their intermediate 
characteristics. (!) high- risk patients treated by hyperthermic 
intraperitoneal chemotherapy (HIPEC); (#) correctly predicted 
metastasis; (+) exitus.
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very recently detected by exome sequencing of the plasma 
of patients refractory to anti- EGFR therapy [32].
In this study, we sought to broaden the scope of 
whole- exome sequencing, using a relatively shallower 
depth to obtain a wider perspective on the circulating 
genome in plasma. This approach represents an easy, 
fast, noninvasive, cost- effective, and affordable strategy 
for identifying patients at high risk for developing metas-
tasis, in contrast to the personalized panels of tumor 
mutations previously proposed as clinical biomarkers, 
for which whole- genome and - exome sequencing may 
not be cost- effective [33].
Tracking of specific mutations by exome sequencing is 
hindered by several factors. One of the major hurdles is 
that the sensitivity of mutation detection is severely affected 
by the concentration of cfDNA in plasma, background 
noise rate, relative abundance of ctDNA, and capture 
efficiency [34]. These approaches usually require sequenc-
ing at a high depth, which considerably increases costs, 
and even at a very high read depth, mutations present 
at extremely low levels might not be distinguishable from 
the sequencing background [35]. Thus, the clinical utility 
of mutational studies based on NGS in plasma of patients 
with low- shedding tumors may be limited.
Through the comparison of the M and N groups, we 
were able to define a set of 379 exons present at different 
levels in cfDNA of metastatic versus nonmetastatic patients; 
some of these exons were significantly over- represented 
in group M, whereas others were present at higher levels 
in group N. This finding led to the definition of a novel 
concept in the field of NGS applications for liquid biopsy: 
“differential presence of exons” (DPE).
Differential detection of exons suggests differential release 
of cfDNA, supporting the idea of an active release of 
nucleic acids by cells, perhaps as a means of intercellular 
communication. Horizontal transfer of DNA between cells 
has been proposed as a pivotal mechanism in the devel-
opment of metastasis both in vitro and in vivo, a phe-
nomenon called genometastasis [36–39]. Consistent with 
this, several publications support the idea that various 
cell types selectively release newly synthesized DNA, prob-
ably associated with lipid and protein complexes, as an 
aspect of homeostatic processes [40, 41]. In some cases, 
these nucleoprotein complexes also exhibit transforming 
activity [42]. Thus, the cfDNA found in plasma of our 
patients could have been, to a greater or lesser extent, 
actively secreted by both tumor and nontumor cells and 
may contribute to metastasis.
In a recent study, read depth coverage patterns associ-
ated to nucleosome occupancy at promoters allowed for 
the identification of expressed and silent genes. Using 
machine learning, expression signatures were inferred, and 
cancer driver genes of metastatic patients were classified 
by copy number gains [43]. Whether our differential pres-
ence profiles are in some way related to the nucleosomal 
fragmentation pattern and changes in gene expression or 
silencing should be further investigated.
When pathway analyses were performed, we found that 
genes from both groups (N and M) were distributed in 
the same pathways. Of note, IPA analysis showed that 
genes from both groups are affecting three major categories 
of functions, but these genes are involved in different 
networks.
For the purposes of this project, we assumed that the 
terms “differentially expressed” and “differentially pre-
sent” were equivalent, although the experiment did not 
involve RNA- seq. To the best of our knowledge, this is 
the first study to apply this kind of approach to analysis 
of cfDNA from patients with cancer. The resulting pro-
files of DPE were used to cluster and classify M and N 
patients, and this information was further processed to 
develop a DPE algorithm that is capable of providing 
a predictive model. Thus, in our series, M and N were 
correctly clustered and clearly separated, whereas unclas-
sifiable patients were intermediate between the two other 
groups. Interestingly, the only two metastatic patients 
from the U group as well as two other patients at high 
risk subjected to second- look HIPEC, a radical prophy-
lactic treatment aimed at preventing recurrence and 
progression, were correctly classified by the DPE algo-
rithm, supporting the potential predictive value of this 
model. Notably, the probabilities of belonging to one 
group or another were always near 0.5, suggesting that 
patients of group U shared common characteristics of 
both groups M and N. In fact, in the verification test, 
the probabilities obtained for M and N samples randomly 
selected from the training set and correctly classified by 
the algorithm were at most 0.68.
These results encourage us to design further studies to 
confirm the predictive and prognostic value of our model, 
as well as to evaluate its utility for early identification of 
high- risk patients.
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